CCM
ATRA icon

CAAS Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

CAAS Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,883
Closed -$3.87M – 1146
2020
Q4 		$3.87M Buy
+7,883
New +$3.64M 0.04% 370

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAAS Capital Management's ATRA Position: Q1 2021 in Review

CAAS Capital Management sold out of Atara Biotherapeutics (ATRA) in Q1 2021, closing a stake of 7,883 shares — an estimated $3.87M sold.

CAAS Capital Management first reported a position in ATRA in Q4 2020 and held it in 1 quarter. The position peaked at $3.87M in Q4 2020. 151 funds tracked by Wall St. Rank hold ATRA as of Q1 2021.

  • CAAS Capital Management reported no remaining Atara Biotherapeutics position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 7,883 Atara Biotherapeutics shares in Q1 2021, an estimated $3.87M.
  • CAAS Capital Management first reported a position in Atara Biotherapeutics in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Atara Biotherapeutics position peaked at $3.87M in Q4 2020.
  • 151 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.